Related Experiment Video
Updated: Jun 21, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Wortmannin inhibits K562 leukemic cells by regulating PI3k/Akt channel in vitro
Qing Wu1, Yan Chen, Guohui Cui
1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. wuqing1221@21cn.cn
Abstract:
The inhibitory effect of wortmannin on leukemic cells and the possible mechanisms were examined. K562 cells were treated with wortmannin of various concentrations (3.125-100 nmol/L) for 0-72 h. MTT assay was used to evaluate the inhibitory effect of wortmannin on the growth of K562 cells. Cell apoptosis was detected by both Annexin-V FITC/PI double-labeled cytometry and transmission electron microscopy (TEM). The expression of p-Akt, T-p-Akt, NF-kappaBp65 and IKK-kappaB was determined by Western blotting and reverse transcription-polymerase chain reaction (RT-PCR). Our results showed that wortmannin obviously inhibited growth and induced apoptosis of K562 cells in vitro in a time- and dose-dependent manner. The IC(50) value of wortmannin for 24 h was 25+/-0.14 nmol/L. Moreover, wortmannin induced K562 cells apoptosis in a dose-dependent manner. TEM revealed typical morphological changes of apoptosis in wortmannin-treated K562 cells, such as chromatin condensation, karyopyknosis, karyorhexis and apoptotic bodies. Additionally, several important intracellular protein kinases such as p-Akt, NF-kappaBp65 and IKK-kappaB experienced degradation of various degrees in a dose-dependent manner both at protein level and transcription level when cultured with wortmannin, but the expression of total Akt showed no change. It is concluded that wortmannin can inhibit the proliferation and induce apoptosis of K562 leukemia cells possibly by down-regulating the survival signaling pathways (PI3K/Akt and NF-kappaB channels).
Insights
Wortmannin effectively inhibits K562 leukemia cell growth and induces apoptosis by down-regulating key survival pathways, including PI3K/Akt and NF-kappaB signaling.
Area of Science:
- Pharmacology
- Molecular Biology
- Cancer Research
Background:
- Leukemia, specifically K562 cell line, presents a significant challenge in cancer therapy.
- Understanding the molecular mechanisms underlying drug action is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the inhibitory effects of wortmannin on K562 leukemia cells.
- To elucidate the underlying molecular mechanisms, focusing on apoptosis induction and signaling pathway modulation.
Main Methods:
- K562 cells were treated with varying concentrations of wortmannin.
- Cell viability was assessed using MTT assay.
- Apoptosis was detected via flow cytometry and transmission electron microscopy (TEM).
- Protein and gene expression of key signaling molecules (p-Akt, NF-kappaBp65, IKK-kappaB) were analyzed using Western blotting and RT-PCR.
Main Results:
- Wortmannin demonstrated significant time- and dose-dependent inhibition of K562 cell proliferation.
- The drug induced apoptosis in K562 cells, evidenced by morphological changes and Annexin-V FITC/PI staining.
- Wortmannin treatment led to the degradation of p-Akt, NF-kappaBp65, and IKK-kappaB at both protein and transcriptional levels, without affecting total Akt expression.
Conclusions:
- Wortmannin inhibits K562 leukemia cell proliferation and induces apoptosis.
- These effects are likely mediated through the downregulation of survival signaling pathways, specifically the PI3K/Akt and NF-kappaB pathways.
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity
PI3K/mTOR/AKT Signaling Pathway
